About this trial
This study evaluates the performance of the study device, FlowSense®, a sensor for non-invasively assessing cerebrospinal fluid (CSF) shunt flow. Subjects with an existing implanted ventricular CSF shunt will be evaluated with the study device in an outpatient setting to determine the negative predictive value (NPV; Part 1, blinded) and explore changes in surveillance imaging, health resource utilization, and visit duration during routine follow-up visits (Part 2, unblinded).
Eligibility criteria
Qualifiers
Existing ventricular cerebrospinal fluid shunt
Age ≥ 2 years old
Region of intact skin overlying an unambiguously identifiable palpable chronically indwelling ventricular shunt that crosses the clavicle; region of skin is appropriate in size for application of the study device
Capable of providing informed consent or have a legal guardian, health care agent, or surrogate decision-maker able to provide informed consent
Disqualifiers
Subject not scheduled to receive outpatient standard of care imaging (CT, MRI, X-ray shunt series) as part of the clinic visit
Presence of more than one distal shunt catheter in the study device measurement region
Presence of an interfering open wound or edema in the study device measurement region
Subject-reported history of adverse skin reactions to silicone adhesives
Trial design
Treatments tested in this trial
- Thermal Anisotropy Measurement Device